Table 2. Candidate plasma markers and their association with clinical variables in a validation set of AMD patients and controls.

Clinical variables (number of patients)	PLTP		MASP-1
	Mean ± standarddeviation (μg/ml)	P value	Mean ± standarddeviation (μg/ml)	P value
Presence of disease, control (61) vs. AMD (99)	0.42 ± 0.08 vs.0.58 ± 0.08	<0.001	7.14 ± 1.26 vs.8.29 ± 1.27	<0.001
Disease severity, early (41) vs. exudative AMD (58)	0.56 ± 0.07 vs.0.60 ± 0.08	0.010	8.12 ± 1.04 vs.8.41 ± 1.41	0.262
Age group, <75 (91) vs. ≥75 years (69)	0.53 ± 0.11 vs.0.51 ± 0.11	0.487	7.84 ± 1.36 vs.7.87 ± 1.41	0.881
Gender, male (55) vs. female (105)	0.53 ± 0.10 vs.0.52 ± 0.12	0.349	7.74 ± 1.29 vs.7.91 ± 1.43	0.464
Smoking, non-smoker (118) vs. current or ex-smoker (29)	0.52 ± 0.12 vs.0.54 ± 0.09	0.257	7.89 ± 1.40 vs.7.85 ± 1.31	0.888
Diabetes mellitus (DM), absent (126) vs. present (34)	0.52 ± 0.11 vs.0.53 ± 0.13	0.826	7.81 ± 1.43 vs.8.02 ± 1.16	0.423
Hypertension (HTN), absent (80) vs. present (80)	0.52 ± 0.10 vs.0.53 ± 0.12	0.549	7.74 ± 1.40 vs.7.97 ± 1.36	0.297
Hyperlipidaemia, absent (117) vs. present (43)	0.52 ± 0.11 vs.0.53 ± 0.13	0.631	7.78 ± 1.32 vs.8.05 ± 1.54	0.316
History of cardio- or cerebrovascular accident, absent (149) vs. present (11)	0.52 ± 0.11 vs.0.48 ± 0.10	0.262*	7.91 ± 1.37 vs.7.10 ± 1.31	0.060*
Cancer history, absent (154) vs. present (6)	0.52 ± 0.11 vs.0.55 ± 0.08	0.507*	7.83 ± 1.38 vs.8.56 ± 1.22	0.205*
ARMS2 rs10490924, G/G (39) vs. G/T or T/T (113)	0.49 ± 0.11 vs.0.54 ± 0.11	0.012	7.50 ± 1.31 vs.8.04 ± 1.34	0.029
CFH rs800292, A/A (23) vs. A/G or G/G (129)	0.55 ± 0.09 vs.0.52 ± 0.11	0.375	7.72 ± 1.01 vs.7.94 ± 1.40	0.488

AMD = age-related macular degeneration; ARMS2 = age-related maculopathy susceptibility 2; CFH = complement factor H; MASP-1 = mannan-binding lectin serine protease 1; PLTP = phospholipid transfer protein.

Boldface indicates statistical significance.

^*Mann-Whitney U test.